A Triple Combination Antiviral Coronavirus Therapy (TriACT) for COVID-19
Status:
Terminated
Trial end date:
2021-02-04
Target enrollment:
Participant gender:
Summary
New outpatient treatments for COVID-19 are urgently needed. There is some evidence that a
combination of three medications currently used to treat other viral infections could be
effective in fighting this new virus. The purpose of this trial is to evaluate the efficacy
of Nitazoxanide (NTZ), Ribavirin (RBV) and Hydroxychloroquine (HCQ) versus placebo in
participants with proven SARS-CoV-2 infection
The study will enroll 70 participants within the 7 days after having been diagnosed with
coronavirus infection. The purpose is to determine if those randomized to 5-day dosing with
the three medication combination have decreased viral load and severity of illness in the 10
days following treatment as compared to those taking placebo. Participants will be actively
followed for 28 days.